Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem Sells 32,930 Shares

Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem sold 32,930 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total transaction of $26,344.00. Following the completion of the transaction, the general counsel now owns 181,188 shares of the company’s stock, valued at $144,950.40. This represents a 15.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Outset Medical Stock Down 3.3 %

OM stock opened at $0.78 on Thursday. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12. Outset Medical, Inc. has a 12 month low of $0.44 and a 12 month high of $5.22. The company’s 50 day simple moving average is $1.01 and its 200-day simple moving average is $1.28.

Institutional Investors Weigh In On Outset Medical

A number of large investors have recently bought and sold shares of OM. Huntington National Bank raised its holdings in shares of Outset Medical by 46.2% in the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock worth $43,000 after acquiring an additional 20,000 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Outset Medical during the 2nd quarter worth about $827,000. Squarepoint Ops LLC increased its position in Outset Medical by 74.1% during the 2nd quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock worth $309,000 after purchasing an additional 34,187 shares in the last quarter. National Bank of Canada FI raised its stake in Outset Medical by 79.2% in the 3rd quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after purchasing an additional 23,164 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Outset Medical in the 2nd quarter valued at about $259,000.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research note on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.